東方生物(688298.SH)2019年度淨利潤升25.6%至8210.52萬元 擬10派2.1元
格隆匯4月27日丨東方生物(688298.SH)發佈2019年年度報告，實現營業收入3.67億元，同比增長28.50%；歸屬於母公司股東的淨利潤8210.52萬元，同比增長25.60%；歸屬於上市公司股東的扣除非經常性損益的淨利潤7601.66萬元，同比增長21.43%；基本每股收益0.91元，擬每10股派發現金紅利2.10元(含税)。
公司是一家專業從事體外診斷產品研發、生產與銷售的公司，目前已完成從抗原抗體等生物原料，到體外診斷試劑以及體外診斷儀器的全產業鏈佈局，形成了以POCT即時診斷試劑為主導產品，重點發展分子診斷、生物原料、診斷儀器和液態生物芯片等產品的業務格局。
公司主要產品為POCT即時診斷試劑，即無需實驗室複雜處理工藝，就可以實施臨牀即時檢測的診斷產品，約佔公司主營業務收入的98%，主要應用於毒品檢測、傳染病檢測、優生優育檢測、腫瘤標誌物檢測和心肌標誌物檢測等領域，而毒品檢測和傳染病檢測是公司的兩大核心產品系列。
目前，毒品檢測產品主要銷往北美市場，面對新型毒品的層出不窮，公司在加拿大設立了抗原研發子公司，與國內的抗體生產子公司同步響應市場，及時開發最新型毒品檢測生物原料，不斷進行產品迭代及產品線擴充，擁有CFDA、FDA、CE、MDL等多項國際認證，品牌效應不斷提升，相關產品已通過澳大利亞及加拿大的專業實驗室評估，性能處於行業前列，終端客户包括世界五百強企業Walmart、Dollar Tree等。
傳染病檢測產品中，艾滋和丙肝檢測試劑盒已經通過歐盟最高級別CE ListA認證；瘧疾即時診斷產品，獲得了比爾及梅琳達·蓋茨基金會資助，專項用於瘧疾檢測試劑盒的WHO預認證，公司有望成為國內首家瘧疾產品通過WHO預認證的企業，通過WHO預認證後，公司將進入WHO體系國際採購供應商名錄，成為全球基金、聯合國人口基金等國際公益組織優先採購的供應商，為公司進一步擴展非洲、東南亞等海外市場提供有力的支持和保證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
